INTRODUCTION
The activation of prothrombin by the phospholipid-bound complex between activated factor X (FXa) and activated factor V (FVa) is a central event of blood coagulation [1] . Factor V (FV) circulates in plasma as a multi-modular (from N-terminus, A1-A2-B-A3-C1-C2 modules) single-chain procofactor (M r l 330 000), and is activated during coagulation by thrombin and\or FXa [2] . FVa comprises the heavy chain (M r l 105 000 ; A1-A2 modules) linked by Ca# + -dependent bonds to the light chain (M r l 75 000 ; A3-C1-C2 modules). The activity of FVa is inhibited by the protein C anticoagulant system [3] . Activated protein C (APC) cleaves the heavy chain of FVa sequentially at Arg&!', Arg$!' and Arg'(*, which leads to complete loss of procoagulant activity [4] . The activity of APC is supported by two cofactors, the vitamin K-dependent protein S and the intact form of FV [5, 6] .
APC resistance has recently been identified as the most common genetic risk factor for venous thrombosis [reviewed in 7] . The observation that purified FV corrects APC resistance linked the phenotype to the FV molecule [8] and the APCresistance phenotype was recently shown to be associated with a single G to A point mutation at nucleotide position 1691, predicting replacement of Arg&!' by Gln [9] [10] [11] [12] . As the APCmediated cleavage at Arg&!' is reported to be necessary for optimal exposure of the other cleavage sites in FVa [4] , a likely molecular explanation for the APC-resistance phenotype is that the Arg&!' to Gln mutation renders FVa partially or completely resistant to APC-mediated degradation. However, there is some controversy in the literature on this topic. Bertina et al. [9] reported FXa-activated FVa : Q&!' [i.e. FVa with glutamine (Q) at position 506], present in aluminium hydroxide-adsorbed plasma from a homozygous individual, to be resistant to APC, Abbreviations used : APC, activated protein C ; FV, factor V ; FVa, activated factor V ; FV : Q 506 , factor V with glutamine (Q) at position 506 ; FV : R 506 , factor V with arginine (R) at position 506 ; FXa, activated factor X ; mAb, monoclonal antibody ; HPC4, mAb against protein C ; HPS54, mAb against protein S ; HFV30, mAb against factor V ; EGF, epidermal growth factor ; PPACK, D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone ; PEG, polyethylene glycol ; APTT, activated partial thromboplastin time.
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degradation than normal FVa, at both high and low phospholipid concentrations. The degradation pattern observed on Western blotting suggested that FVa : Q&!' was not cleaved at position 506. However, it was slowly cleaved at Arg$!', which explains the partial APC sensitivity of FVa : Q&!'. FV is initially activated during clotting and then rapidly inactivated in a process which depends on the integrity of the protein C anticoagulant system. During clotting of APC-resistant plasma, FV : Q&!' was activated in a normal fashion, but then only partially inactivated. In conclusion, the reduced sensitivity of FVa : Q&!' to APC-mediated degradation is the molecular basis for the life-long hypercoagulable state which constitutes a risk factor for thrombosis in APC-resistant individuals.
whereas the thrombin-activated form was found to be APC sensitive. On the other hand, Sun et al. [13] demonstrated that 50 % of thrombin-activated FV from two heterozygous individuals was APC-resistant, suggesting that thrombin-activated FV : Q&!' is resistant to APC-mediated degradation. To resolve this controversy, we have isolated FV : Q&!' from the plasma of a homozygous individual and characterized some of its functional properties. Our results demonstrate that the APC-resistance phenotype is conveyed both by FV : Q&!' and FVa : Q&!' and that FVa : Q&!' is resistant to cleavage by APC at position 506, which is the likely molecular mechanism for the APC-resistance phenotype. During the preparation of this article, a paper by Kalafatis et al. [14] appeared, which reports on the purification of FV : Q&!' from two individuals with homozygosity for the Arg&!' to Gln mutation. Kalafatis and colleagues demonstrated that mutated FVa (FVa : Q&!') is not cleaved at position 506 by APC, but that APC slowly inactivates FVa : Q&!' by cleavages both at Arg$!' and Arg'(*. Our present study confirms and extends the results reported by Kalafatis et al. [14] .
MATERIALS AND METHODS

Proteins
Human protein C was purified from fresh frozen plasma essentially as previously described [15] , but with monoclonal antibody (mAb) (HpC-4) affinity chromatography as the last purification step. mAb HpC-4, which recognizes a calciumstabilized epitope in the first epidermal growth factor-like (EGF) module of human protein C [16] , was coupled to Affigel 10 (Biorad) according to the manufacturer's instructions. The column was equilibrated with 50 mM Tris\HCl\0.15 M NaCl\2 mM CaCl # , pH 7.4, containing 10 mM benzamidine, and after sample application, the column was washed with the same buffer containing 1 M NaCl instead of 0.15 M NaCl. Protein C was eluted with 0.1 M acetic\acetate, pH 4.0, containing 10 mM benzamidine. Protein C was activated by thrombin as described [17] . Human protein S [18] and bovine α-thrombin [19] were purified as reported in the respective references. Bovine FXa, purified and activated as described earlier [20, 21] , was a gift from Dr. J. Stenflo (University Hospital, Malmo$ ). mAb HPC4 (note, this is not the antibody which was used for purification), which recognizes the activation peptide of protein C [22] , was a gift from Dr. C. T. Esmon (Oklahoma Medical Research Foundation, OK, U.S.A.). This antibody, which blocks the activation of protein C, does not inhibit the function of APC. mAb HFV30 was directed against human FV [8] . mAb HPS54, directed against the first EGF-module of human protein S, efficiently blocks the APC-cofactor activity of protein S [23] .
Purification of factor V from plasma
APC-resistant plasma was obtained from an individual with homozygosity for the Arg&!' to Gln mutation in the FV gene by plasmapheresis, after informed consent. Control plasma from subjects with normal APC ratios was obtained from the local blood bank. FV was purified from plasma as previously outlined [24] , but with the following modifications. Freshly frozen citrated plasma (10 ml for each preparation) was thawed at 37 mC and the following protease inhibitors were added : 1 mM PMSF, 10 mM benzamidine, 1.5 µg\ml aprotinin, 50 µg\ml soybean trypsin inhibitor and 1 µM -phenylalanyl--prolyl--arginine chloromethyl ketone (PPACK) (final concentrations). The plasma was subjected to barium citrate absorption and polyethylene glycol (PEG)-6000 precipitation as described. The 8-12 % PEG pellet was resuspended in 20 mM Tris\0.1 M NaCl\2 mM CaCl # , pH 7.5, containing 0.5 µM PPACK, and applied to a QSepharose fast-flow (Pharmacia) column (0.5i4 cm). The adsorbed proteins were eluted at 100 ml\h with a 20 ml linear gradient of NaCl (0.2-0.8 M). Fractions containing FV coagulant activity were pooled and subjected to (NH % ) # SO % precipitation (75 % saturation). The precipitate was resuspended in 50 mM Tris\0.1 M NH % Cl\10 mM CaCl # , pH 7.5, containing 0.5 µM PPACK, and applied to a Sephacryl S-300 (Pharmacia) column (1i22 cm) equilibrated in the same buffer (flow rate 1 ml\min). The fractions were analysed by SDS\PAGE, Western blotting and with FV clotting assay. Fractions containing FV were pooled, dialysed against 50 mM Tris\0.15 M NaCl\2 mM CaCl # , pH 7.5, and stored at k80 mC after the addition of 0.1 % PEG-6000 (final concentration). The FV concentration in the pool was quantified by ELISA.
Electrophoretic and immunological methods
SDS\PAGE, using 5-15 % gradient gels, was performed as described previously [25] . Samples were reduced with dithiothreitol and subsequently alkylated with iodoacetamide. The proteins were transferred to membranes [Immobilon (polyvinylidene difluoride) ; Millipore] and FV was detected using a rabbit polyclonal antiserum against human FV (Dako) as primary antibody, and an alkaline phosphatase-conjugated swine antirabbit antiserum as secondary antibody (Dako). The intensity of immunoreactive bands was quantified using a laser densitometer (Molecular Dynamics). FV was measured by ELISA using standard procedures. Microtitre plates (Linbro\Titertek) were coated with a polyclonal antibody against human FV (10 µg\ml ; Dako), samples were added and incubated for 2 h. Bound FV was detected with biotinylated HFV30 (2.25 µg\ml). The wells were washed and incubated with a solution containing streptavidin and biotinylated horseradish peroxidase (Dako A\S) for 30 min. After multiple washes, the amount of attached peroxidase was measured with 1,2-phenylenediamine (Dako A\S) and H # O # diluted in 0.5 M citrate, pH 4. The reaction was stopped by addition of 0.5 M H # SO % and the absorbance measured at 490 nm. Pooled human plasma was used to construct the standard curve.
Activation of factor V and inactivation of factor Va
FV (50 nM) in 50 mM Tris\0.15 M NaCl\2 mM CaCl # , pH 7.5, containing 0.1 % PEG-6000, was activated using bovine α-thrombin (3 units\ml final concentration) at 37 mC for 15 min. Thrombin was then neutralized by the addition of hirudin (final concentration 4.5 units\ml ; Sigma). Alternatively, FV was activated by bovine FXa (final concentration of 5 nM) at 37 mC for 15 min in the presence of 50 µM phospholipid (the same preparation as is used in the Coatest Factor VIII kit from Chromogenix ; a gift from Dr. S. Rose! n at Chromogenix). Conditions used for FV activation by thrombin and FXa were chosen to yield maximal FVa activity. FVa was incubated with human APC at 37 mC in the presence of 50 µM or 50 nM phospholipid vesicles. Aliquots were removed at various times and assayed for FV procoagulant activity and analysed by SDS\PAGE and Western blotting.
Clotting assays
FV procoagulant activity was measured with a clotting assay, as described [24] . FV-deficient plasma (50 µl ; Stago) was incubated with sample (50 µl) at 37 mC for 30 s. Simplastin Excel (100 µl; Organon Teknica) was then added and the clotting time recorded. FV activity was calculated from standard curves based on human pooled plasma, assuming a plasma concentration of 1 unit\ml. In a modified APC-resistance test [26] , purified FV or FVa (50 µl) was added to FV-deficient plasma (50 µl) and incubated at 37 mC with activated partial thromboplastin time (APTT) reagent (50 µl ; Coatest APC-resistance, Chromogenix) for 200 s. Clotting was initiated with 40 mM CaCl # (50 µl) in the presence or absence of APC. The APC ratio is the clotting time measured in the presence of APC divided by the clotting time obtained in the absence of APC. The thrombin-generation potential of normal and APC-resistant plasma was measured essentially as described by Hemker et al. [27] . The reaction mixtures, consisting of 200 µl of plasma and 50 µl of 50 mM Tris\0.1 M NaCl, pH 7.35, were kept at 37 mC and magnetically stirred. After 5 min, coagulation was initiated by the addition of 50 µl of thromboplastin (Simplastin Excel ; final dilution 1\100) in CaCl # (10 mM final concentration). This dilution of thromboplastin yielded clotting times of around 35 s in both normal and APCresistant plasma. Every 10 s, 2 µl aliquots were drawn and added to microtitre wells containing 93 µl of buffer [50 mM Tris\0.1 M NaCl\20 mM EDTA (pH 7.9)\1 % PEG-6000] and 5 µl of 4 mM S-2238, prewarmed at 30 mC. After 10 min, the reactions were stopped by addition of 60 µl of concentrated acetic acid and the absorbance read at 405 nm.
Statistical analysis
The results are expressed as meanspS.E.M. of 3-5 different experiments.
RESULTS
Purification of FV : Q 506
FV : Q&!' was purified from plasma obtained from an APCresistant individual with homozygosity for the G to A mutation at nucleotide position 1691 in the FV gene, which predicts replacement of Arg&!' with Gln. The purification procedure was devised to allow rapid isolation of FV from small amounts of plasma ; approx. 15 µg of FV was obtained from 10 ml of normal or APC-resistant plasma. The purity of the isolated FV was between 50 and 70 %, as judged by its specific activity (approximately 65 units\mg) and by silver-stained SDS\PAGE. Figure 1A ). Similar results were obtained when the thrombin-activated forms of FV : Q&!' or FV : R&!' were used and also when the two FV forms were activated by FXa instead of by thrombin ( Figure 1B ). This demonstrated that the APCresistance phenotype was conveyed not only by intact FV : Q&!' but also by its activated counterpart.
APC resistance conveyed by FV
High concentrations of protein S do not correct APC resistance
Protein S is a cofactor of APC in the degradation of FVa but it is not known whether protein S is equally important for the three different APC-cleavage sites in FVa. To elucidate whether the APC resistance of FVa : Q&!' could be overcome by high concentrations of protein S, increasing concentrations of protein S were added to plasma containing FVa : Q&!' or FVa : R&!' and the APC response was measured ( Figure 2) . A dose-dependent increase in the APC ratio was observed in plasma containing FVa : R&!', whereas plasma containing FVa : Q&!' remained APC resistant also at high concentrations of protein S. This demonstrates that the APC-resistance phenotype is not corrected by high concentrations of protein S, suggesting that the rate of APC-cleavage at Arg$!' is unaffected by high concentrations of protein S. In the absence of APC, the addition of protein S did not affect the results of the APTT assay. 
APC-mediated inhibition of procoagulant activities of FVa : Q 506 and FVa : R 506
The ability of APC to inhibit the procoagulant activities of thrombin-activated FVa : Q&!' and FVa : R&!' was investigated in a system containing purified components (Figure 3) . To elucidate the importance of the phospholipid vesicles in these reactions, the experiment was performed at high and low phospholipid concentrations (50 µM and 50 nM). At both phospholipid concentrations, FVa : R&!' was more efficiently inactivated than FVa : Q&!'. However, at high phospholipid levels, the proteolytic reactions proceeded at higher rates than at low phospholipid concentrations and less APC was required to inhibit the activity of both FVa : R&!' and FVa : Q&!'. This indicated that APCmediated degradation of both normal and mutated FVa is a phospholipid-oriented process. At both phospholipid concentrations, the rates of inactivation of FVa : Q&!' were approx. 10-fold lower than those of FVa :R&!', and the dose-response curves suggested that FVa : Q&!' was approx. 10-fold less sensitive to APC than was FVa : R&!' (Figure 3) . (Figure 4) . The polyclonal antiserum against human FV that was used, mainly recognized epitopes present in the heavy chain (M r l 105 000) or in the B module (M r l 150 000), and it reacted only weakly with the light chain (M r l 75 000). For a proper interpretation of the degradation pattern on the Western blotting, it is important to note that the antiserum reacted with the C-terminal half of the heavy chain but not with the rest of the chain ; the epitopes were located within residues 507-709 of the A2-module (illustrated in Figure 4b ). In the presence of 50 µM phospholipid, APC efficiently degraded FVa : R&!'. The loss of the heavy chain coincided with the loss of FV activity and with the appearance of a doublet band (M r approx. 28 000), which corresponded to the immunoreactive Cterminal half of the A2 domain of FV [4] . The rate of degradation of the heavy chain of FVa : Q&!' was slower than that of FVa : R&!', and proteolytic fragments were only observed at the highest concentrations of APC. The loss of the heavy chain of FVa : Q&!' coincided with loss of FV activity and with the appearance of a heterogeneous band with M r of approx. 56 000 (Figure 4) , which represented the A2 domain of FVa after cleavage at Arg$!', and possibly at Arg'(* [14] . The pattern of APC-mediated degradation on this Western blotting was consistent with the results of Kalafatis et al. [14] , demonstrating that FVa : Q&!' was not cleaved at position 506.
APC-mediated degradation of
Figure 5 Importance of protein C and protein S in the activation of FV during clotting and subsequent FVa inactivation
APTT reagent (final dilution 1/30) was mixed with normal or APC-resistant plasma (300 µl) and incubated during magnetic stirring at 37 mC for 3 min before recalcification. Clotting occurred between 2.5 and 3 min. Aliquots were removed at intervals, diluted in 50 mM Tris/0.15 M NaCl, pH 7.4, containing 0.1 % PEG-6000, and assayed for FV activity. Normal (A) or APC-resistant (B) plasma was incubated for 3 min at 37 mC with 65 µg/ml of polyclonal anti-(protein C) antibody (Dako) (4), 100 µg/ml of HPC4 mAb (against activation peptide) (=), or with 50 mM Tris/0.15 M NaCl, pH 7.4 ( ,$), before recalcification. Normal (C) or APC-resistant (D) plasma was incubated for 3 min at 37 mC with 50 µg/ml of mAb against protein S (HPS54) (W), or with 50 mM Tris/0.15 M NaCl, pH 7.4 ( ,$), before recalcification. The differences in maximum FV activity (at 4 min) observed in APC-resistant plasma in the presence or absence of antibodies (B and D) were not statistically significant (unpaired t-test).
Activation and inactivation of FV : Q 506 and FV : R 506 during coagulation
During blood coagulation in itro, the initial activation of FV is followed by a loss of FVa activity, which is caused by FVa degradation mediated by APC which is formed during the clotting reaction [28] . To investigate whether the activation and inactivation processes were affected by the Arg&!' to Gln mutation, clotting of normal and APC-resistant plasma was induced and the FV activity measured ( Figure 5 ). The use of diluted APTT reagent, rather than platelet-rich plasma [28] , resulted in relatively slow activation of the coagulation system, which allowed detailed monitoring of the process. The initial FV activation appeared to be similar in the two plasmas, but FVa formed in APC-resistant plasma was considerably more stable than that formed during clotting of normal plasma. That the FVa inactivation was in fact mediated by APC was evident from the reduced inactivation rate of FVa in normal plasma observed upon the addition of either polyclonal or monoclonal antibodies against human protein C (mAb HPC4, which inhibits protein C activation [22] ). In contrast, the FVa activity in APC-resistant plasma remained unaffected by the protein C antibodies ( Figures  5A and 5B) . Indeed, in the presence of protein C antibodies, the rates of FVa inactivation of normal and APC-resistant samples were quite similar. To investigate the role of protein S in the FVa inactivation that followed upon clotting, a mAb against protein S (HPS54), which completely inhibited APC-cofactor activity of protein S [23] , was added ( Figures 5C and 5D) . In normal plasma, HPS54 was equally efficient at inhibiting FVa inactivation as the anti-(protein C) antibodies, whereas the presence
Figure 6 Thrombin-generation potential of normal and APC-resistant plasma
Thrombin-generation curves of normal ( ) and APC-resistant plasma ($) were measured using the chromogenic substrate S-2238 as described in the Materials and methods section.
of HPS54 in APC-resistant plasma did not significantly affect the course of FVa inactivation. These results suggest that the difference in FVa inactivation rates between normal and APCresistant plasma is related to the different sensitivities of FVa : R&!' and FVa : Q&!' to degradation by APC.
Thrombin-generation potential of normal and APC-resistant plasma
During coagulation of plasma, a burst of thrombin generation occurs during and after the formation of the clot. The thrombingeneration potential of normal and APC-resistant plasma was found to be essentially identical (Figure 6 ), indicating that the FV : Q&!' mutation did not influence the process to any major extent. In both plasmas, the thrombin concentration peaked approx. 2 min after initiation of the coagulation process and this was followed by a slow loss of thrombin activity, presumably as a result of inhibition of thrombin by antithrombin III. In this experiment, a diluted thromboplastin reagent was used to initiate the clotting process. As a result, the rate of thrombin generation was low and presumably very little APC was formed during the first minutes of the clotting reaction. This is probably why normal and APC-resistant plasma yielded identical thrombingeneration curves.
DISCUSSION
APC resistance, which is the most prevalent genetic risk factor of thrombosis, is linked to a single point-mutation in the FV gene, which predicts replacement of Arg&!' in one of the APC-cleavage sites with Gln [9] [10] [11] [12] . Partially purified FV from individuals with heterozygosity for FV : Q&!' has been shown to transfer APC resistance to FV-deficient plasma [13] . We now demonstrate that purified FV : Q&!', from an individual with homozygosity for the Arg&!' to Gln mutation, conveys APC resistance to FV-deficient plasma, which is in agreement with the conclusion that the APCresistance phenotype is caused by a molecular defect residing in the FV molecule. Thrombin-or FXa-activated FV : Q&!' was also found to convey APC resistance, showing the molecular defect to be present in the parts of FV which constitute FVa.
During degradation of FVa by APC, three peptide bonds are sequentially cleaved in the heavy chain, at Arg&!', Arg$!' and Arg'(* [4] . FVa : Q&!' is therefore expected to be less sensitive towards APC than FVa : R&!'. However, there is some disagreement in the literature as to the question of whether or not thrombin-activated FVa : Q&!' is resistant to APC [9, 14] . Our results, together with those recently reported by Kalafatis et al. [14] , help resolve this problem. Kalafatis et al. [14] reported that the Arg&!' to Gln mutation was associated with resistance to APC-mediated cleavage at position 506. However, FVa : Q&!' was shown to be inactivated by APC-mediated cleavages both at Arg$!' and Arg'(*, which led to the formation of two major heavy-chain fragments of 45 kDa (A1 domain) and 56\54 kDa (A2 domain). The conclusion from our study is the same, i.e. FVa : Q&!' is not completely resistant to APC even though there is a major difference in APC sensitivity between FVa : Q&!' and FVa : R&!'. APC was found to be approx. 10-fold less efficient at degrading thrombin-activated FVa : Q&!' than thrombinactivated FVa : R&!', at both high and low phospholipid concentrations. The same difference in APC sensitivity between normal and mutated FV was observed after activation of FV with FXa. The rate of degradation of both normal and mutated FV was dependent on the phospholipid concentration. At low phospholipid levels, the degradation of FVa : Q&!' proceeded very slowly, and even after a 1 h incubation with a high concentration of APC only 30 % of FVa : Q&!' was inactivated. It is possible that the reported differences in the APC sensitivity of mutated FVa are related to differences in experimental conditions, e.g. in the concentration of phospholipid that has been used. The influence of the phospholipid concentration on the rate of FVa degradation may be of physiological significance. Under normal conditions, the amount of negatively charged phospholipids in contact with blood is low. The decreased APC sensitivity of FVa : Q&!', as compared to FVa : R&!', at such low phospholipid concentrations probably leads to a hypercoagulable state which contributes to the increased thrombotic tendency.
During coagulation, FV is rapidly activated to FVa, which is then inactivated by APC which is formed during the clotting process [28] . In normal and APC-resistant plasma, no difference in the activation process of FV to FVa was observed and the thrombin generation potential was found to be similar in the two plasmas. However, after coagulation, normal FVa was rapidly inactivated while the FVa activity in the APC-resistant sample was only slowly and partially lost. The addition of antibodies to protein C reverted the inactivation of FVa in normal plasma to the degree observed in APC-resistant plasma. This agrees with the concept that APC plays an essential role in the inactivation of FVa after clotting in itro. The effect of protein S on the stability of FVa during clotting of plasma was also examined with the help of a mAb against human protein S, which efficiently inhibited the APC-cofactor function of protein S. In normal plasma, FVa inactivation was counteracted by the protein S antibody, whereas the FVa activity of APC-resistant plasma was not significantly affected by the antibody. These results suggested that the impaired FVa inactivation observed after coagulation of APC-resistant plasma was caused by the poor sensitivity of FVa : Q&!' to APC.
In conclusion, in addition to confirming the results of Kalafatis et al. [14] that FV : Q&!' is not cleaved at position 506 by APC, our results provide new insights into the molecular mechanisms of APC resistance. Thus, we demonstrate that not only intact, but also thrombin-and FXa-activated FV : Q&!', convey APC resistance on plasma and that APC resistance is not corrected by high concentrations of protein S. Moreover, the rate of APCReceived 19 July 1995/30 August 1995 ; accepted 7 September 1995 mediated inactivation of FVa : Q&!' was shown to depend on the phospholipid concentration, APC resistance being particularly pronounced at low levels of phospholipid. Furthermore, FV : Q&!' was found to be activated normally during clotting, whereas the APC-mediated FV inhibition that followed upon clotting was delayed in APC-resistant plasma as compared to normal plasma. The increased stability of mutated FVa leads to increased thrombin generation, a hypercoagulable state and a life-long increased risk of thrombosis [12] . Heterozygosity for FV : Q&!' is associated with a 5-10-fold increased risk of venous thromboembolism. The observation that even homozygosity is a relatively mild risk factor (50-100-fold increased risk) (reviewed in [7] ), suggests that there are alternative mechanisms by which APC regulates the coagulation process. Normal degradation of FVIIIa and slow degradation of FVa : Q&!' as a result of cleavages at Arg$!' and Arg'(* by APC help explain why APC resistance is such a mild risk factor for thrombosis.
